Metastatic bladder cancer: a review of current management.
dc.contributor.author | Fletcher, Andrew | |
dc.contributor.author | Choudhury, Ananya | |
dc.contributor.author | Alam, Nooreen | |
dc.date.accessioned | 2012-03-20T12:49:16Z | |
dc.date.available | 2012-03-20T12:49:16Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Metastatic bladder cancer: a review of current management. 2011, 2011:545241 ISRN Urol | en_GB |
dc.identifier.issn | 2090-5815 | |
dc.identifier.pmid | 22084801 | |
dc.identifier.doi | 10.5402/2011/545241 | |
dc.identifier.uri | http://hdl.handle.net/10541/216113 | |
dc.description.abstract | Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to ISRN urology | en_GB |
dc.title | Metastatic bladder cancer: a review of current management. | en |
dc.type | Article | en |
dc.contributor.department | Department of Palliative and Supportive Care, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. | en_GB |
dc.identifier.journal | ISRN Urology | en_GB |
html.description.abstract | Bladder cancer continues to result in substantial morbidity and mortality for affected individuals. Advances in the management of metastatic bladder cancer have been limited. Chemotherapy with platinum-based regimes remains the mainstay of first-line treatment. Studies investigating alternative regimes have offered no survival advantage. Targeted therapies may offer benefit either as single agent or in combination with chemotherapy. Symptoms due to metastatic bladder cancer impact patients' quality of life, and therefore holistic management is vital. Such management includes radiotherapy, bisphosphonates, and the involvement of specialist palliative care services. This review will discuss the current management for metastatic bladder cancer, future potential treatment modalities, and the evidence to support the management strategies. |
This item appears in the following Collection(s)
-
All Christie Publications
-
Clinical Oncology
Clinical Oncology